GlassScriptPhysician profile
Regina Brooks Hall
NPI 1417049404
$2,045.26
in general payments reported to CMS, 2019-2025
22 companies · $723 in 2025
The $723 reported for 2025 was more than what 80% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $174 · 2022: $493 · 2023: $338 · 2024: $317 · 2025: $723.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,377.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,377.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $594.98 | 2021-2025 | |
| Pfizer INC. | $212.69 | 2022-2025 | |
| Amgen INC. | $211.17 | 2021-2023 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $154.85 | 2022-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $150.99 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $126.28 | 2021-2025 | Camzyos, Eliquis |
| Medtronic, INC. | $97.16 | 2024 | Onyx Frontier |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $90.08 | 2022-2023 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $64.29 | 2021-2025 | Farxiga |
| Amarin Pharma, INC. | $55.17 | 2022 | |
| Esperion Therapeutics, INC. | $46.88 | 2021-2023 | Nexletol |
| Novo Nordisk INC | $39.41 | 2025 | Wegovy, Ozempic, Rybelsus |
| Alnylam Pharmaceuticals INC. | $30.39 | 2025 | Onpattro |
| Sioux Surgical INC | $29.25 | 2025 | |
| Merck Sharp & Dohme LLC | $27.72 | 2022-2023 | Verquvo |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Octapharma USA, INC. | $26.12 | 2025 | Fibryga |
| Scpharmaceuticals INC. | $19.66 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $16.21 | 2024 | Opsumit |
| Kiniksa Pharmaceuticals, LTD. | $14.38 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $13.73 | 2024 | Arcalyst |
| Regeneron Healthcare Solutions, INC. | $12.20 | 2022 | |
| Chiesi USA, INC. | $11.65 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Regina Brooks Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.